Stay updated with breaking news from Research Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acumen Pharmaceuticals, Inc. presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AßO targeting antibody therapy in early AD, at the...
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid...
Topline results for ACU193, the first clinical stage amyloid beta oligomer -directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early... | June 13, 2023
Today in Washington ------------------------------------------------------------- This Diary is filed daily. ** Indicates new events -------------------------------------------------------------
Today in Washington ------------------------------------------------------------- This Diary is filed daily. ** Indicates new events -------------------------------------------------------------